Utilization of Immunotherapy in Patients with Cancer Treated in Routine Care Settings: A Population-Based Study Using Health Administrative Data
暂无分享,去创建一个
G. Rodrigues | M. Trudeau | M. Krzyzanowska | N. Leighl | J. Raphael | L. Richard | P. Blanchette | M. Lam
[1] Eun Jeong Min,et al. Uptake and Survival Outcomes Following Immune Checkpoint Inhibitor Therapy Among Trial-Ineligible Patients With Advanced Solid Cancers. , 2021, JAMA oncology.
[2] D. Schrag,et al. Association Between First-Line Immune Checkpoint Inhibition and Survival for Medicare-Insured Patients With Advanced Non–Small Cell Lung Cancer , 2021, JAMA network open.
[3] I. Kern,et al. Prognostic value of PD-L1 expression in patients with unresectable stage III non-small cell lung cancer treated with chemoradiotherapy , 2020, Radiation Oncology.
[4] S. Lipsitz,et al. Adoption of immunotherapy in the community for patients diagnosed with metastatic melanoma , 2019, Journal of Immunotherapy for Cancer.
[5] Kelvin K. W. Chan,et al. Demographic characteristics and cost of treatment among oncology patients in a publicly funded system, the Ontario Trillium Drug Program: a retrospective cohort study. , 2019, CMAJ open.
[6] Vinay Prasad,et al. Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs , 2019, JAMA network open.
[7] A. Monfared,et al. Real-world systemic therapy treatment patterns for squamous cell carcinoma of the head and neck in Canada. , 2019, Current oncology.
[8] A. Abernethy,et al. Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical Trials , 2018, JAMA oncology.
[9] Bohuslav Melichar,et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal‐Cell Carcinoma , 2018, The New England journal of medicine.
[10] D. Carbone,et al. First-Line Nivolumab in Stage IV or Recurrent Non-Small Cell Lung Cancer , 2017 .
[11] C. Gridelli,et al. Real-world treatment patterns for patients receiving second-line and third-line treatment for advanced non-small cell lung cancer: A systematic review of recently published studies , 2017, PloS one.
[12] K. Kelly,et al. Increasing Rates of No Treatment in Advanced‐Stage Non–Small Cell Lung Cancer Patients: A Propensity‐Matched Analysis , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[13] S. Culine,et al. Pembrolizumab as Second‐Line Therapy for Advanced Urothelial Carcinoma , 2017, The New England journal of medicine.
[14] A. Mariotto,et al. Antineoplastic Treatment of Advanced-Stage Non-Small-Cell Lung Cancer: Treatment, Survival, and Spending (2000 to 2011). , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] Y. Shentu,et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.
[16] L. Paz-Ares,et al. Current Challenges in Cancer Treatment. , 2016, Clinical therapeutics.
[17] David Moher,et al. The REporting of Studies Conducted Using Observational Routinely-Collected Health Data (RECORD) Statement: Methods for Arriving at Consensus and Developing Reporting Guidelines , 2015, PloS one.
[18] Yiping Yang,et al. Cancer immunotherapy: harnessing the immune system to battle cancer. , 2015, The Journal of clinical investigation.
[19] D. Schadendorf,et al. Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.
[20] T. Vandenberg,et al. A framework for the organization and delivery of systemic treatment , 2009, Current oncology.